Residual Prostate Cancer After Radiotherapy: A Study of Radical Cystoprostatectomy Specimens

Urology

Volumn 72, Issue 3, 2008, Pages 654-658

  Kaplan, David J ^a   Crispen, Paul L ^a   Greenberg, Richard E ^a   Chen, David Y T ^a   Viterbo, Rosalia ^a   Buyyounouski, Mark K ^a   Horwitz, Eric M ^a   Uzzo, Robert G ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; CYSTECTOMY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT INDICATION;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION ONCOLOGY; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 50249123076     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.11.020     Document Type: Article

References (19)

1. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977-1984
2. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
3. Cookson M.S., Aus G., Burnett A.L., et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177 (2007) 540-545
4. Consensus statement: guidelines for PSA following radiation therapy: American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
5. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
6. Crook J., Malone S., Perry G., et al. Postradiotherapy prostate biopsies: what do they really mean?. Results for 498 patients. Int J Radiat Oncol Biol Phys 48 (2000) 355-367
7. Vance W., Tucker S.L., de Crevoisier R., et al. The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome. Int J Radiat Oncol Biol Phys 67 (2007) 828-833
8. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
9. Magi-Galluzzi C., Sanderson H., and Epstein J.I. Atypia in nonneoplastic prostate glands after radiotherapy for prostate cancer: duration of atypia and relation to type of radiotherapy. Am J Surg Pathol 27 (2003) 206-212
10. Cheng L., Cheville J.C., and Bostwick D.G. Diagnosis of prostate cancer in needle biopsies after radiation therapy. Am J Surg Pathol 23 (1999) 1173-1183
11. Stamey T.A., Caldwell M., McNeal J.E., et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297-1301
12. Miyake H., Sakai I., Harada K., et al. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease. Int J Urol 12 (2005) 270-274
13. Alschibaja M., Wegner M., Massmann J., Funk A., Hartung R., and Paul R. Prostate cancer volume - can it be predicted preoperatively?. Urol Int 75 (2005) 354-359
14. Zhang L., Loblaw A., and Klotz L. Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol 176 (2006) 1392-1397 discussion 1397-1398.
15. Warlick C.A., Allaf M.E., and Carter H.B. Expectant treatment with curative intent in the prostate-specific antigen era: triggers for definitive therapy. Urol Oncol 24 (2006) 51-57
16. Dugan T.C., Shipley W.U., Young R.H., et al. Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels. J Urol 146 (1991) 1313-1316
17. Gaudin P.B., Zelefsky M.J., Leibel S.A., et al. Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues. Am J Surg Pathol 23 (1999) 1021-1031
18. Stone N.N., Stock R.G., White I., et al. Patterns of local failure following prostate brachytherapy. J Urol 177 (2007) 1759-1763 discussion 1763-1764.
19. Pollack A., Zagars G.K., Antolak J.A., et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 54 (2002) 677-685